# A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

> **NCT00486811** · PHASE3 · COMPLETED · sponsor: **Grünenthal GmbH** · enrollment: 990 (actual)

## Conditions studied

- Pain
- Knee Osteoarthritis

## Interventions

- **DRUG:** Tapentadol ER (100 to 250 mg twice daily)
- **DRUG:** Matching Placebo (twice daily)
- **DRUG:** Oxycodone CR (20 to 50 mg twice daily)

## Key facts

- **NCT ID:** NCT00486811
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 990 (ACTUAL)
- **Last updated:** 2019-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486811, "A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00486811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*